南华生物
(000504)
| 流通市值：20.91亿 | | | 总市值：22.21亿 |
| 流通股本：3.11亿 | | | 总股本：3.30亿 |
| 报告期 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 218,260,076.45 | 217,507,472.66 | 205,070,966.14 | 218,148,260.73 |
| 应收票据及应收账款 | 162,608,054.37 | 166,831,777.6 | 168,247,960.76 | 158,759,054.35 |
| 应收账款 | 162,608,054.37 | 166,831,777.6 | 168,247,960.76 | 158,759,054.35 |
| 预付款项 | 4,164,587.17 | 2,344,486.8 | 2,658,022.72 | 3,342,322.78 |
| 其他应收款合计 | 21,252,800.73 | 21,517,121.61 | 23,890,896.19 | 25,209,934.02 |
| 存货 | 7,272,355.8 | 5,978,315.13 | 5,672,847.36 | 4,500,707.82 |
| 其他流动资产 | 4,419,335.05 | 3,531,916.84 | 4,070,927.77 | 4,590,544.63 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 419,448,529.08 | 419,313,942.3 | 420,281,160.4 | 416,235,973.16 |
| 非流动资产: | | | | |
| 长期股权投资 | 5,479,883.06 | 5,479,883.06 | 5,484,304.54 | 5,484,304.54 |
| 固定资产 | 14,732,155.63 | 19,922,382.21 | 19,668,947.07 | 20,362,355.83 |
| 使用权资产 | 13,276,153.48 | 14,587,249.41 | 15,413,610.08 | 15,571,324.23 |
| 无形资产 | 454,942.8 | 469,068.57 | 350,450.98 | 361,258.18 |
| 商誉 | 8,441,122.41 | 8,441,122.41 | 8,441,122.41 | 8,441,122.41 |
| 长期待摊费用 | 79,911,935.74 | 81,801,121.92 | 83,863,695.83 | 85,668,447.78 |
| 递延所得税资产 | 383,791.58 | 383,791.58 | 294,805.64 | 294,805.64 |
| 其他非流动资产 | 59,226.41 | 259,226.41 | 628,735.59 | 645,135.59 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 122,739,211.11 | 131,343,845.57 | 134,145,672.14 | 136,828,754.2 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 542,187,740.19 | 550,657,787.87 | 554,426,832.54 | 553,064,727.36 |
| 流动负债: | | | | |
| 短期借款 | 38,126,871.29 | 58,123,362.93 | 61,084,485.69 | 63,082,774.56 |
| 应付票据及应付账款 | 79,564,017.22 | 80,782,912.12 | 82,245,399.77 | 82,031,637.91 |
| 应付账款 | 79,564,017.22 | 80,782,912.12 | 82,245,399.77 | 82,031,637.91 |
| 合同负债 | 143,615,625.1 | 140,050,792.41 | 129,701,399.39 | 119,737,249.21 |
| 应付职工薪酬 | 3,110,018.61 | 3,808,946.4 | 4,244,897.19 | 6,460,621.37 |
| 应交税费 | 3,364,959.68 | 1,690,738.4 | 5,739,775.21 | 9,272,563.37 |
| 其他应付款合计 | 161,660,906.97 | 163,025,112.69 | 161,550,634.47 | 162,005,632.42 |
| 应付股利 | 931,102.81 | 931,102.81 | 931,102.81 | 931,102.81 |
| 一年内到期的非流动负债 | 65,743.16 | 3,058,228.07 | 65,743.16 | 2,813,466.66 |
| 其他流动负债 | 10,996,957.95 | 10,749,388.85 | 11,491,030.16 | 9,747,718.68 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 440,505,099.98 | 461,289,481.87 | 456,123,365.04 | 455,151,664.18 |
| 非流动负债: | | | | |
| 租赁负债 | 15,455,479.64 | 13,597,473.09 | 16,190,642.52 | 14,788,620.4 |
| 长期应付款 | - | - | - | 1,000,000 |
| 递延收益 | 1,351,584 | 1,394,297 | 1,437,010 | 1,829,723 |
| 递延所得税负债 | 282,140.3 | 313,749.73 | 353,747 | 410,519.91 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 17,089,203.94 | 15,305,519.82 | 17,981,399.52 | 18,028,863.31 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 457,594,303.92 | 476,595,001.69 | 474,104,764.56 | 473,180,527.49 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 311,573,901 | 311,573,901 | 311,573,901 | 311,573,901 |
| 资本公积 | 170,816,843.3 | 170,816,843.3 | 170,816,843.3 | 170,816,843.3 |
| 盈余公积 | 34,545,734.18 | 34,545,734.18 | 34,545,734.18 | 34,545,734.18 |
| 未分配利润 | -502,678,556.56 | -512,138,429.86 | -505,141,319.97 | -503,165,274.86 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 14,257,921.92 | 4,798,048.62 | 11,795,158.51 | 13,771,203.62 |
| 少数股东权益 | 70,335,514.35 | 69,264,737.56 | 68,526,909.47 | 66,112,996.25 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 84,593,436.27 | 74,062,786.18 | 80,322,067.98 | 79,884,199.87 |
| 负债和股东权益合计 | 542,187,740.19 | 550,657,787.87 | 554,426,832.54 | 553,064,727.36 |
| 公告日期 | 2023-10-31 | 2023-08-30 | 2023-04-29 | 2023-04-21 |
| 审计意见(境内) | | | | 标准无保留意见 |